GlassScriptPhysician profile
Ana Rossi
NPI 1629277710
$4,946.52
in general payments reported to CMS, 2019-2025
24 companies · $3,338 in 2025
The $3,338 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.50 · 2020: $38.78 · 2021: $175 · 2022: $142 · 2023: $541 · 2024: $684 · 2025: $3,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,659 · Food and Beverage: $1,850 · Education: $54.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,659.04 |
| Food and Beverage | $1,849.72 |
| Education | $54.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $2,673.65 | 2023-2025 | Tarpeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.65 | 2020-2025 | Xifaxan, Plenvu |
| Veloxis Pharmaceuticals, INC. | $315.02 | 2020-2025 | Envarsus |
| Mallinckrodt Hospital Products INC. | $267.75 | 2022-2025 | Terlivaz, Acthar |
| Intercept Pharmaceuticals, INC. | $253.70 | 2022-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $171.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Novartis Pharmaceuticals Corporation | $131.64 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $122.68 | 2022-2025 | Ultomiris |
| Astellas Pharma US INC | $100.23 | 2022-2023 | Cresemba |
| Abbvie INC. | $79.68 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $67.52 | 2024-2025 | Iqirvo |
| Travere Therapeutics, INC. | $66.73 | 2022-2025 | Filspari |
| Ani Pharmaceuticals, INC. | $47.44 | 2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $46.36 | 2021-2024 | |
| Orphalan INC | $39.15 | 2024-2025 | Cuvrior |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $34.31 | 2023-2025 | Lokelma |
| Pfizer INC. | $27.50 | 2019 | |
| Novo Nordisk INC | $26.61 | 2025 | Wegovy |
| Azurity Pharmaceuticals, INC. | $23.85 | 2025 | |
| Merck Sharp & Dohme LLC | $22.05 | 2025 | Prevymis |
| Invivyd INC | $19.96 | 2025 | Pemgarda |
| Alnylam Pharmaceuticals INC. | $19.22 | 2023 | Onpattro |
| Melinta Therapeutics, LLC | $17.91 | 2025 | Rezzayo |
| Lemaitre Vascular, INC. | $7.88 | 2023 | Anastoclip Gc 8cm (Medium) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.